Project Background
A European biotechnology research team developed a BRD4-targeting PROTAC series containing a triazole-connected linker and a VHL-recruiting ligand. Several analogs showed strong biochemical binding to both BRD4 and VHL, but cellular degradation results were inconsistent across leukemia-derived cell lines. The client needed to determine whether poor degradation was caused by weak permeability, instability, or insufficient ternary complex formation.
Technical Challenges
The PROTAC series had high molecular weight and variable linker polarity. Some analogs showed poor aqueous recovery, while others produced moderate degradation despite similar biochemical affinity. A standard activity assay alone could not explain the performance gap among compounds.
BOC Sciences Solutions
- Cellular Uptake Profiling: We developed an LC-MS/MS method to quantify intracellular PROTAC concentration after 0.5, 1, 2, and 4 hours of exposure, with recovery controls to correct for compound loss during washing and extraction.
- PAMPA and Cell-Based Comparison: Twelve linker analogs were evaluated using PAMPA and target-cell uptake assays to separate passive diffusion effects from cell-specific accumulation behavior.
- Degradation Correlation: Intracellular exposure data were compared with BRD4 degradation readouts, DC50, and Dmax values to identify analogs with the best balance between uptake and degradation efficiency.
Project Outcomes
BOC Sciences identified three analogs with substantially higher intracellular accumulation than the original compound. The best-performing structure used a shorter mixed alkyl-PEG linker that reduced excessive polarity while maintaining flexibility for ternary complex formation. This analog achieved stronger BRD4 degradation at lower extracellular concentration, while two highly polar analogs were deprioritized due to poor cellular uptake despite acceptable binding profiles. The client used these findings to guide the next round of linker SAR design.
Project Background
A US-based drug discovery group was optimizing a kinase-targeting PROTAC built with a CRBN-recruiting ligand and a rigid aromatic linker. The lead compound produced potent degradation in one engineered cell model but weak activity in a second disease-relevant cell line. The client suspected transporter-mediated efflux and requested a permeability-focused investigation before redesigning the scaffold.
Technical Challenges
The compound showed good apparent solubility but low cellular accumulation in preliminary experiments. Because the target and E3 ligase were both expressed in the weak-response cell line, the project required a method that could evaluate directional transport, intracellular retention, and degradation response together.
BOC Sciences Solutions
- Bidirectional Transport Testing: We performed MDCK-based directional permeability studies and calculated Papp and efflux ratio to determine whether active export contributed to low intracellular exposure.
- Washout and Retention Analysis: The lead compound and six modified analogs were tested in uptake-retention experiments to compare intracellular persistence after compound removal.
- Structure-Guided Optimization: Based on the data, we recommended reducing exposed aromatic surface area and adjusting linker polarity to improve retention while preserving kinase ligand orientation.
Project Outcomes
Among seven evaluated compounds, two analogs showed lower efflux ratios and improved intracellular retention. The most balanced analog retained measurable intracellular levels for a longer post-washout window and produced more consistent kinase degradation in the disease-relevant cell line. The study helped the client avoid unnecessary changes to the target ligand and instead focus optimization on linker architecture and exposed polarity.
Clarifies Poor Degradation Results
